Loading...
Loading...
Rockwell Medical
RMTI, a fully-integrated biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD) with
innovative products for the treatment of iron deficiency, secondary
hyperparathyroidism and hemodialysis, announced today that it has
received notice from the Canadian Intellectual Property Office that
it has obtained patent issuance for its proprietary GMP formulation
for Soluble Ferric Pyrophosphate (SFP), the Company's lead
investigational drug that provides iron replacement to hemodialysis
patients with CKD.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in